Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension

Journal of Hypertension

Volumn 18, Issue 7, 2000, Pages 927-933

  Takeda, Yoshiyu ^a   Inaba, Satoru ^b   Furukawa, Kenji ^a   Fujimura, Akio ^c   Miyamori, Isamu ^b   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cyclosporine; Endothelin; Hypertension; Natriuretic peptide; Neutral endopeptidase inhibitor; Nitric oxide

Indexed keywords

CYCLOSPORIN; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE SYNTHASE; SINORPHAN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033941712     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018070-00015     Document Type: Article

References (31)

1. 1 Benett WN, Porter GA. Cyclosporine-associated hypertension. Am J Med 1988; 85:131-133.
2. 2 Schnabel FR, Wait RB, Aaronson P, Kahng KU. Effect of cyclosporine A administration on vascular reactivity in the rabbit. Transplant Proc 1989; 21:918-921.
3. 3 Takeda Y, Miyamori I, Yoneda T, Takeda R. Endothelin-1 release from the mesenteric arteries of cyclosporine-treated rats. Eur J Pharmacol 1992; 213:445-447.
4. 4 Takeda Y, Miyamori I, Yoneda T, Takeda R. Increased concentration of endothelin messenger RNA in the mesenteric arteries of cyclosporine-induced hypertensive rats. Am J Hyperten 1993; 6:427-430.
5. 5 Takeda Y, Miyamori I, Wu P, Yoneda T, Furukawa K, Takeda R. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 1995; 26:932-936.
6. 6 Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 1998; 102:2061-2071.
7. 7 Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998; 97:2323-2330.
8. 8 Richards AM, Crozier IG, Kosoglou T, Rallings M, Espiner EA, Nicolls MG, et al. Endopeptidase 24.11 inhibition by SCH 52595 in essential hypertension. Hypertension 1993; 22:119-126.
9. 9 Miyamori I, Brown MJ, Dollery CT. Single-dose captopril administration in DOCA/salt rats: reduction of hypotensive effect by indomethacin. Clin Exp Hypertens 1980; 2:935-945.
10. 10 Takeda Y, Miyamori I, Furukawa K, Inaba S, Mabuchi H. Mechanisms of FK506-induced hypertension in rat. Hypertension 1999; 33:130-136.
11. 11 Stasch J-P, Hirth-Dietrich C, Ganten D, Wegner M. Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene. Am J Hypertens 1996; 9:795-802.
12. 12 Palestine AG, Austin HA, Balow JE. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986; 314:1293-1297.
13. 13 Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn K-H. ACE inhibitor versus β-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33:862-868.
14. 14 Lipkin GW, Thuraisingham R, Dawnay ABS, Harwood SM, Raine AEG. Acute reversal of cyclosporine nephrotoxicity by neutral endopeptidase inhibition in stable renal transplant recipients. Transplantation 1997; 64:1001-1017.
15. 15 Hirata Y, Suzuki E, Hayakawa H, Matsuoka H, Sugimoto T, Omata M, et al. Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats. J Cardiovasc Pharmacol 1994; 23:283-290.
16. 16 Lang CC, Hendeson IS, Macher R, Stewart WK, Struthers AD. Atrial natriuretic factor improves renal function and lowers systolic blood pressure in renal allograft recipients treated with cyclosporin A. J Hypertens 1992; 10:482-486.
17. 17 Niranjan V, Telemaque S, deWit D, Gerard RD, Yanagisawa M. Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats. J Clin Invest 1996; 98:2364-2372.
18. 18 Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91:2144-2149.
19. 19 Lee ME, Temizir DH, Clifford JA, Quertermous T. Cloning of the GATA-binding protein that regulates endothelin-1 gene expression in endothelial cells. J Biol Vhem 1991; 266:16188-16192.
20. 20 Moncada S, Palmer RMJ, Higgs EA, Nitric oxide: physiology, pathology, and pharmacology. Pharmacol Rev 1991; 43:109-142.
21. 21 Panza JA, Quyyumi, AA, Brush JE.Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
22. 22 Rees D, Ben-Ishay D, Moncada S. Nitric oxide and the regulation of blood pressure in the hypertension-prone and hypertension-resistant Sabra rat. Hypertension 1996; 28:367-371.
23. 23 Marumo T, Nakaki T, Hishikawa K, Suzuki H, Kato R, Saryta T. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 1995; 25:764-768.
24. 24 Sudhir K, Macgregor JS, DeMarco T, De Groot CJM, Taylor RN, Chou TM, et al. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardia and resistance coronary arteries. Circulation 1994; 90:3018-3023.
25. 25 Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosuppressant FK 506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA 1993; 90:9808-9812.
26. 26 Oriji GK, Keiser HR. Role of nitric oxide in cyclosporine A - induced hypertension. Hypertension 1998; 32:849-855.
27. 27 Lopez-Ongil S, Saura M, Rodriguez-Puyol D, Rodriguez-Puyol M, Lamas S. Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells. Am J Physiol 1996; 271(3 pt 2):H1072-H1078.
28. 28 Stroes ESG, Luscher TF, de Groot FG, Koomans HA, Rabelink TJ. Cyclosporin A increases nitric oxide activity in vivo. Hypertension 1997; 29:570-575.
29. 29 Hirata Y, Suzuki Y, Suzuki E, Hayakawa H, Kimura K, Goto A, et al. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors. J Hypertension 1994; 12:367-374.
30. 30 Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994; 7:943-947.
31. 31 Lipkin GW, Dawnay ABS, Cattell WR, Raine AEG. Chronic neutral endopeptidase inhibition ameliorates experimental cyclosporin nephrotoxicity. Proc Int Soc Nephrol 1993.